阿拉林调节RyR2和SERCA2,以改善心力衰竭中的心脏功能,并保留喷射分数
Jinshuang Li1, Dawei Xu2, Ce Shi3
1Department of Cardiology, Suqian Hospital Affiliated of Xuzhou Medical University, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu.
European journal of histochemistry : EJH
|November 4, 2024
概括
阿拉林通过减少氧化应激和恢复平衡来保护心脏功能,在心力衰竭中保护排气分数 (HFpEF). 这种可以作为HFpEF管理的治疗标.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生理学 生理学 生理学
背景情况:
- 由于人口老龄化,心脏衰竭与保存的喷射分数 (HFpEF) 是一个越来越令人担忧的问题.
- 高氧化带来复杂的治疗挑战,通常涉及氧化应激和处理障碍.
- 心肌结构损伤和腹功能障碍是HFpEF的标志.
研究的目的:
- 在HFpEF的老鼠模型中研究阿拉林的心脏保护机制.
- 阐明阿拉林如何影响HFpEF中的氧化应激和离子通道活性.
- 确定阿拉林作为HFpEF的潜在治疗点.
主要方法:
- 使用HFpEF大鼠模型和H9C2心脏细胞.
- 评估了阿拉林对氧化应激标志物的影响.
- 研究了阿拉林对NADPH氧化酶1 (NOX1),RyR2和SERCA2的调节.
主要成果:
- 高FpEF条件会增加氧化应激,导致心肌损伤和腹功能障碍.
- 阿拉林通过与NOX1.1相互作用来减轻氧化应激.
- 阿拉林通过调节RyR2和SERCA2来使Ca2+稳态正常化,改善心脏功能.
结论:
- 阿拉林在HFpEF中显示出显著的心脏保护作用.
- 阿拉林的机制涉及减轻氧化应激和恢复平衡.
- 阿拉林为治疗HFpEF提供了一个有前途的治疗途径.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
Rheumatic Heart Disease I: Introduction
3
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
3
Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Heart Failure Drugs: Inotropic Agents
525
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
525


